EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

Silvia Morbelli; Giuseppe Esposito; Javier Arbizu; Henryk Barthel; Ronald Boellaard; Nico I Bohnen; David J Brooks; Jacques Darcourt; John C Dickson; David Douglas; Alexander Drzezga; Jacob Dubroff; Ozgul Ekmekcioglu; Valentina Garibotto; Peter Herscovitch; Phillip Kuo; Adriaan Lammertsma; Sabina Pappata; Iván Peñuelas; John Seibyl; Franck Semah; Livia Tossici-Bolt; Elsmarieke Van de Giessen; Koen Van Laere; Andrea Varrone; Michele Wanner; George Zubal; Ian Law

doi:https://doi.org/10.1007/s00259-020-04817-8

EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

Silvia Morbelli, Giuseppe Esposito, Javier Arbizu, Henryk Barthel, Ronald Boellaard, Nico I Bohnen, David J Brooks, Jacques Darcourt, John C Dickson, David Douglas, Alexander Drzezga, Jacob Dubroff, Ozgul Ekmekcioglu, Valentina Garibotto, Peter Herscovitch, Phillip Kuo, Adriaan Lammertsma, Sabina Pappata, Iván Peñuelas, John SeibylFranck Semah, Livia Tossici-Bolt, Elsmarieke Van de Giessen, Koen Van Laere, Andrea Varrone, Michele Wanner, George Zubal, Ian Law

Research output: Contribution to journal › Article › Academic › peer-review

133 Citations (Scopus)

Abstract

PURPOSE: This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes.

METHODS: Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking.

CONCLUSION: All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.

Original language	English
Pages (from-to)	1885-1912
Number of pages	28
Journal	European journal of nuclear medicine and molecular imaging
Volume	47
Issue number	8
DOIs	https://doi.org/10.1007/s00259-020-04817-8
Publication status	Published - 1 Jul 2020

Keywords

Brain
DAT
DOPA
PET
Parkinson
Parkinsonian syndromes
SPECT

Access to Document

https://doi.org/10.1007/s00259-020-04817-8

Cite this

Morbelli, S., Esposito, G., Arbizu, J., Barthel, H., Boellaard, R., Bohnen, N. I., Brooks, D. J., Darcourt, J., Dickson, J. C., Douglas, D., Drzezga, A., Dubroff, J., Ekmekcioglu, O., Garibotto, V., Herscovitch, P., Kuo, P., Lammertsma, A., Pappata, S., Peñuelas, I., ... Law, I. (2020). EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European journal of nuclear medicine and molecular imaging, 47(8), 1885-1912. https://doi.org/10.1007/s00259-020-04817-8

@article{564deb00d29349e5b825434f3874d3d1,

title = "EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0",

abstract = "PURPOSE: This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes.METHODS: Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking.CONCLUSION: All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.",

keywords = "Brain, DAT, DOPA, PET, Parkinson, Parkinsonian syndromes, SPECT",

author = "Silvia Morbelli and Giuseppe Esposito and Javier Arbizu and Henryk Barthel and Ronald Boellaard and Bohnen, {Nico I} and Brooks, {David J} and Jacques Darcourt and Dickson, {John C} and David Douglas and Alexander Drzezga and Jacob Dubroff and Ozgul Ekmekcioglu and Valentina Garibotto and Peter Herscovitch and Phillip Kuo and Adriaan Lammertsma and Sabina Pappata and Iv{\'a}n Pe{\~n}uelas and John Seibyl and Franck Semah and Livia Tossici-Bolt and {Van de Giessen}, Elsmarieke and {Van Laere}, Koen and Andrea Varrone and Michele Wanner and George Zubal and Ian Law",

year = "2020",

month = jul,

day = "1",

doi = "https://doi.org/10.1007/s00259-020-04817-8",

language = "English",

volume = "47",

pages = "1885--1912",

journal = "European journal of nuclear medicine and molecular imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "8",

}

Morbelli, S, Esposito, G, Arbizu, J, Barthel, H, Boellaard, R, Bohnen, NI, Brooks, DJ, Darcourt, J, Dickson, JC, Douglas, D, Drzezga, A, Dubroff, J, Ekmekcioglu, O, Garibotto, V, Herscovitch, P, Kuo, P, Lammertsma, A, Pappata, S, Peñuelas, I, Seibyl, J, Semah, F, Tossici-Bolt, L, Van de Giessen, E, Van Laere, K, Varrone, A, Wanner, M, Zubal, G & Law, I 2020, 'EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0', European journal of nuclear medicine and molecular imaging, vol. 47, no. 8, pp. 1885-1912. https://doi.org/10.1007/s00259-020-04817-8

TY - JOUR

T1 - EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

AU - Morbelli, Silvia

AU - Esposito, Giuseppe

AU - Arbizu, Javier

AU - Barthel, Henryk

AU - Boellaard, Ronald

AU - Bohnen, Nico I

AU - Brooks, David J

AU - Darcourt, Jacques

AU - Dickson, John C

AU - Douglas, David

AU - Drzezga, Alexander

AU - Dubroff, Jacob

AU - Ekmekcioglu, Ozgul

AU - Garibotto, Valentina

AU - Herscovitch, Peter

AU - Kuo, Phillip

AU - Lammertsma, Adriaan

AU - Pappata, Sabina

AU - Peñuelas, Iván

AU - Seibyl, John

AU - Semah, Franck

AU - Tossici-Bolt, Livia

AU - Van de Giessen, Elsmarieke

AU - Van Laere, Koen

AU - Varrone, Andrea

AU - Wanner, Michele

AU - Zubal, George

AU - Law, Ian

PY - 2020/7/1

Y1 - 2020/7/1

N2 - PURPOSE: This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes.METHODS: Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking.CONCLUSION: All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.

AB - PURPOSE: This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes.METHODS: Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking.CONCLUSION: All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.

KW - Brain

KW - DAT

KW - DOPA

KW - PET

KW - Parkinson

KW - Parkinsonian syndromes

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=85084518521&partnerID=8YFLogxK

U2 - https://doi.org/10.1007/s00259-020-04817-8

DO - https://doi.org/10.1007/s00259-020-04817-8

M3 - Article

C2 - 32388612

SN - 1619-7070

VL - 47

SP - 1885

EP - 1912

JO - European journal of nuclear medicine and molecular imaging

JF - European journal of nuclear medicine and molecular imaging

IS - 8

ER -

EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

Abstract

Keywords

Access to Document

Other files and links

Cite this